CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

The therapeutic effects of WSY-0702 on benign prostatic hyperplasia in RWPE-1

  • Received : 2017.01.06
  • Accepted : 2017.04.07
  • Published : 2017.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Benign prostatic hyperplasia (BPH) is one of the major diseases of the urinary system in older men. WSY-0702 is the extracted from the traditional medicinal plant; Seoritae, and it has effects of anti-obesity, chronic cervical pain, and anti-oxidant. The present study aimed to investigate the therapeutic potential of WSY-0702 in the prevention and treatment of BPH. Several parameters including inflammatory mediators, hormones, and oxidative stress (OS) have been considered to play a role in the development of BPH. Prostate tissue damage and OS may lead to compensatory cellular proliferation with resulting hyperplastic growth. An in vitro study showed that proliferation inhibited the human prostate epithelial cell line RWPE-1 in a dose-dependent manner. In cell line, the cell cycle at the G2/M and G0/G1 phase and downregulated the expression of CyclineB1 (CCNB1) and CyclineD1 (CCND1). In addition, we measured the $H_2O_2$-induced OS damage using RWPE-1 cells. We examined the relative expression of protein involved in the regulation of prostate apoptosis: transforming growth factor (TGF)-${\beta}$, a negative growth factor able to induced prostate apoptosis under physiological conditions. These results suggest that WSY-0702 that can inhibit the growth of prostate epithelial cell by a mechanism that may involve arresting the cell cycle and downregulating CCNB1 and CCND1 expression. In addition, WSY-0702 exposure resulted in significant protective effects in $H_2O_2$-stressed PWPE-1 cells by reduction in TGF-${\beta}$ levels.

Keywords

References

  1. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009;15:3654-3662. https://doi.org/10.1158/1078-0432.CCR-08-3293
  2. Bagchi D, Sen CK, Bagchi M, Atalay M. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. Biochemistry. 2004;69:75-80.
  3. Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedulla F, Alama A. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res. 1999;5:1837-1842.
  4. Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genistein-stimulated adherence of prostate cancer cells is associated with binding of focal adhesion kinase to beta-1- intergrin. Clin Exp Metastasis. 1996;14:389-398. https://doi.org/10.1007/BF00123398
  5. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013;23:5-10. https://doi.org/10.1097/MOU.0b013e32835abd4a
  6. Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS. Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol. 2011;300:H1210-H1221. https://doi.org/10.1152/ajpheart.01210.2010
  7. Chakrabarti L, Wang BD, Lee NH, Sandler AD. A mechanism linking Id2-TGF-beta crosstalk to reversible adaptive plasticity in neuroblastoma. PLos One. 2013;8:e83521. https://doi.org/10.1371/journal.pone.0083521
  8. Evans BA, Griffiths K, Morton MS. Inhibition of 5 -reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995;147:295-302. https://doi.org/10.1677/joe.0.1470295
  9. Farnsworth WE. Estrogen in the etiopathogenesis of BPH. Prostate. 1999;41:263-274. https://doi.org/10.1002/(SICI)1097-0045(19991201)41:4<263::AID-PROS7>3.0.CO;2-0
  10. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985;121:78- 90.
  11. Gohla G, Krieglstein K, Spittau B. Tieg3/K1f11 induces apoptosis in OLI-neu cells and enhances the TGF-beta signaling pathways by transcriptional repression of Smad7. J Cell Biochem. 2008;104:850-861. https://doi.org/10.1002/jcb.21669
  12. Gunthert AR, Grundker C, Hollmann K, Emons G. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophy Res Commun. 2002;294:11-15. https://doi.org/10.1016/S0006-291X(02)00427-8
  13. Hirota Y, Tsukazaki T, Yonekura A, Miyazaki Y, Osaki M, Shindo H, Yamashita S. Activation of specific MEK-ERK cascade is necessary for TGF-beta signaling and crosstalk with PKA and PKC pathways in cultured rat articular chondrocytes. Osteoarthritis Cartilage. 2000;8:241-247. https://doi.org/10.1053/joca.1999.0297
  14. Hogan KA, Ravindran A, Podolsky MA, Glick AB. The TGFbeta1 pathway is required for NFkappaB dependent gene expression in mouse keratinocytes. Cytokine. 2013;64:652-659. https://doi.org/10.1016/j.cyto.2013.09.004
  15. Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGFbeta and hedgehog signaling in cancer. FEBS Lett. 2012;586:2016-2025. https://doi.org/10.1016/j.febslet.2012.05.011
  16. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Role of oxidative stress in prostate cancer. Cancer lett. 2009;282:125-136. https://doi.org/10.1016/j.canlet.2008.12.011
  17. Kumar R, Verma V, Sarswat A, Maikhuri JP, Jain A, Jain RK, Sharma VL, Dalela D, Gupta G. Selective estrogen modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms-action of two new agents. Invest New Drugs. 2012;30:582-593. https://doi.org/10.1007/s10637-010-9620-2
  18. Kyprianou N, Isaacs JT. Expression of transforming growth factor-in rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol. 1989;3:1515-1522. https://doi.org/10.1210/mend-3-10-1515
  19. Lauth M, Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle. 2007;6:2458-2463. https://doi.org/10.4161/cc.6.20.4808
  20. Lee YS, Choi BK, Lee HJ, Lee DR, Cheng J, Lee WK, Yang SH, Suh JW. Monascus pilosus-fermented black soybean inhibits lipid accumulation in adipocytes and in high-fat dietinduced obese mice. Asian Pac J Trop Med. 2015;8:276-282. https://doi.org/10.1016/S1995-7645(14)60330-8
  21. Letamendia A, Labbe E, Attisano L. Transcriptional regulation by Smads: crosstalk vetween the TGF-beta and Wnt pathways. J Bone Joint Surg Am. 2001;83-A Suppl 1:S31-39.
  22. Lewis JG, Nakajin S, Ohno S, Warnock A, Florkowski CM, Elder PA. Circulating levels of isoflavones and markers of 5 - reductase activity are higher in Japanese compared with New Zealand males: what is the role of curcylating steroids in prostate disease? Steroids.2005;70:974-979. https://doi.org/10.1016/j.steroids.2005.06.008
  23. Liu J, Wen XY, Zhang XQ, Pu HM, Kan J, Jin CH. Extraction, characterization and in vitro antioxidant activity of polysaccharides from black soybean. Int J Biol Macromol. 2015;72:1182-1190. https://doi.org/10.1016/j.ijbiomac.2014.08.058
  24. Liu M, Li XQ, Weber C, Lee CY, Brown J, Liu RH. Antioxidant and antiproliferative activities of raspberries. J Agric Food Chem. 2002;50:2926-2930. https://doi.org/10.1021/jf0111209
  25. Liu Z, Schwimer J, Liu D, Greenway FL, Anthony CT, Woltering EA. Black raspberry extract and fractions contain angiogenesis inhibitors. J Agric Food Chem. 2005;53:3909- 3915. https://doi.org/10.1021/jf048585u
  26. Li X, Tian F, Wang F. The effects of black soybean (Glycine max var.) on chronic cervical pain of sedentary office workers in a northern Chinese population. Food Funct. 2015;6:3500- 3511. https://doi.org/10.1039/C5FO00659G
  27. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology. 1990;127:2963-2968. https://doi.org/10.1210/endo-127-6-2963
  28. Massague J. The transforming growth factor- family. Annu Rew Cell Biol. 1990;6:597-641 https://doi.org/10.1146/annurev.cb.06.110190.003121
  29. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, Prat J, Cigudosa JC, Matias-Guiu X, Palacios J. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene. 2003;22:6115-6118. https://doi.org/10.1038/sj.onc.1206868
  30. Moreno CS. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch and PI3K pathways. Am J Pathol. 2010;176:518-527. https://doi.org/10.2353/ajpath.2010.090657
  31. Nickel JC, Roehrborn CG, O'leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of chemopevention trial. J Urol. 2007;1:896-900.
  32. Nyhan KC, Faherty N, Murray G, Cooey LB, Godson C, Crean JK, Brazil DP. Jagged/Nach signaling is required for a subset of TGF-beta1 responses in human kidney epithelial cells. Biochim Biophy Acta. 2010;1803:1386-1395. https://doi.org/10.1016/j.bbamcr.2010.09.001
  33. Patel ND, Parsons JK. Epidermiology and etiology of benign prostate htperplasia and bladder outlet obstruction. Indian J Urol. 2014;30:170-176. https://doi.org/10.4103/0970-1591.126900
  34. Patel RP, Boersma BJ, Crawford JH, Hogg N, Kirk M, Kalyanaraman B, Parks DA, Barnes S, Darley-Usmar V. Antioxidant mechanisms of isoflavones in lipid systems: paradoxical effects of peroxyl radical scavenging. Free Radic Biol Med. 2001;12:1570-1581.
  35. Qu X, Shen L, Zheng Y, Cui Y, Feng Z, Liu F, Liu J. A signal transduction pathway from TFG-beta1 to SKP2 via Akt1 and c- Myc and its correlation with progression in human melanoma. J Invest Dermatol. 2014;134:159-167. https://doi.org/10.1038/jid.2013.281
  36. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206-238. https://doi.org/10.1080/21551197.2012.702534
  37. Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming factor beta in cultured uterine epithelial cells. Proc Natl Acad Sci USA. 1991;88:3412-3415. https://doi.org/10.1073/pnas.88.8.3412
  38. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003;21:744-757. https://doi.org/10.1081/CNV-120023773
  39. Schindler R, Mentlein R. Rlavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J Nutr. 2006;136:1477-1482. https://doi.org/10.1093/jn/136.6.1477
  40. Seystahl K, Tritschler I, Szabo E, Tabatabai G, Weller M. Differential regulation of TGF-beta-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro oncol. 2015;17:254-265. https://doi.org/10.1093/neuonc/nou218
  41. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390-2400. https://doi.org/10.1038/sj.onc.1204383
  42. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131-136. https://doi.org/10.1038/ncb0502-e131
  43. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
  44. Suzuki K, Inaba S, Takeuchi H, Takezawa Y, Fukabori Y, Suzuki T, Imai K, Yamanaka H, Honma S. Endocrinal environment of benign prostatic hyperplasia-relationships of sex steroid hormone levels with age and the size of the prostate. Nihon Hinyokika Gakkai Zasshi. 1992;83:664-671.
  45. Vanhara P, Bryja V, Horvath V, Kozubik A, Hampl A, Smarda J. c-Jun induces apoptosis of starved BM2 monoblasts by activating cyclin A-CDK2. Biochem Biophys Res Commun. 2007;353:92-97. https://doi.org/10.1016/j.bbrc.2006.11.124
  46. Walker L, Millena AC, Strong N, Khan SA. Expression of TGF-beta3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement oh PI3-kinase/AKT signaling pathways. Clin Exp Metastasis. 2013;30:13-23. https://doi.org/10.1007/s10585-012-9494-0
  47. Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y, Mori M. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer. 2013;49:1725-1740. https://doi.org/10.1016/j.ejca.2012.12.002
  48. Yanagihara K, Tsumuraya M. Transforming growth factor beta induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res. 1992;52:4042-4045.
  49. Yousef MI, Kamel KI, Esmail AM, Baghdadi HH. Antioxidant activities and lipid lowering effects of isoflavone in male rebbits. Food Chem Toxicol. 2004;42:1497-1503. https://doi.org/10.1016/j.fct.2004.04.012